文献速递淋巴瘤

弥漫大B细胞淋巴瘤幸存者免疫健康受损

Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2020-02-21

这项回顾性队列研究纳入加州癌症登记处21,690例弥漫大B细胞淋巴瘤(DLBCL)幸存者,并与乳腺癌、前列腺癌、头颈癌和黑色素瘤幸存者比较,分析诊断后1-10年自身免疫病、免疫缺陷和感染的发生率。结果显示DLBCL幸存者多种免疫相关疾病的发生率比显著升高,且多数在诊断后5-10年仍持续偏高;除体液免疫缺陷与利妥昔单抗使用相关外,其余风险升高不能由化疗、干细胞移植或利妥昔单抗解释。

要点

  • DLBCL幸存者病毒性和真菌性肺炎发生率比最高达10.8倍,脑膜炎最高达5.3倍。
  • 体液免疫缺陷发生率比最高达17.6倍,自身免疫性血细胞减少最高达12倍。
  • 多数免疫相关风险在诊断后5-10年仍持续升高,提示长期免疫失调。

核心结论

  • DLBCL幸存者存在持续且显著升高的自身免疫病、免疫缺陷和感染风险,可能反映淋巴瘤或治疗导致的长期免疫失调,并可能增加幸存期的发病和死亡。

研究设计与样本

  • 回顾性队列研究,比较加州癌症登记处21,690例DLBCL幸存者与乳腺癌、前列腺癌、头颈癌和黑色素瘤幸存者。
  • 将登记记录链接至全州数据库,纳入医院、急诊和门诊手术就诊记录,分析诊断后1-10年的免疫相关疾病发生率。

主要发现

  • DLBCL幸存者多种免疫相关疾病的发生率比高于其他癌症幸存者,病毒性和真菌性肺炎发生率比最高达10.8倍。
  • 脑膜炎发生率比最高达5.3倍,体液免疫缺陷最高达17.6倍,自身免疫性血细胞减少最高达12倍。
  • 多数疾病的发生率比在诊断后5-10年的晚期幸存阶段仍保持高位。
  • 除体液免疫缺陷外,风险升高不能由化疗、干细胞移植或利妥昔单抗暴露解释;体液免疫缺陷的发生率比在DLBCL治疗引入利妥昔单抗后持续更高。

临床怎么用

  • 对DLBCL长期幸存者应关注感染、免疫缺陷和自身免疫病的监测与长期随访管理。

局限性

  • 为回顾性队列研究,免疫相关疾病基于就诊数据库记录识别,可能存在漏诊或编码偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS: In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS: We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION: To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shree T, Li Q, Glaser SL, et al. Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020. PMID: 32083991. doi:10.1200/JCO.19.01937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。